SG10201703732VA - A composition for treating diabetes or diabesity comprising oxyntomodulin analog - Google Patents

A composition for treating diabetes or diabesity comprising oxyntomodulin analog

Info

Publication number: SG10201703732VA
Authority: SG; Singapore
Prior art keywords: diabesity; composition; treating diabetes; oxyntomodulin analog; oxyntomodulin
Prior art date: 2012-11-06

Application number

SG10201703732VA

Inventor

Jin Sun Kim

Dae Jin Kim

Sang Hyun Lee

Sung Youb Jung

Se Chang Kwon

Original Assignee

Hanmi Pharm Ind Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-06

Filing date

2013-11-06

Publication date

2017-06-29

2013-11-06 Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd

2017-06-29 Publication of SG10201703732VA publication Critical patent/SG10201703732VA/en

Links

206010012601 diabetes mellitus Diseases 0.000 title 1
PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG10201703732VA 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog SG10201703732VA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
KR1020120124724A KR101993393B1 (en)	2012-11-06	2012-11-06	A composition for treating diabetes or diabesity comprising oxyntomodulin analog

Publications (1)

Publication Number	Publication Date
SG10201703732VA true SG10201703732VA (en)	2017-06-29

Family

ID=50684885

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10202110636WA SG10202110636WA (en)	2012-11-06	2013-11-06	A composition for treating diabetes or diabesity comprising oxyntomodulin analog
SG10201703732VA SG10201703732VA (en)	2012-11-06	2013-11-06	A composition for treating diabetes or diabesity comprising oxyntomodulin analog
SG11201503420QA SG11201503420QA (en)	2012-11-06	2013-11-06	A composition for treating diabetes or diabesity comprising oxyntomodulin analog

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10202110636WA SG10202110636WA (en)	2012-11-06	2013-11-06	A composition for treating diabetes or diabesity comprising oxyntomodulin analog

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201503420QA SG11201503420QA (en)	2012-11-06	2013-11-06	A composition for treating diabetes or diabesity comprising oxyntomodulin analog

Country Status (29)

Country	Link
US (2)	US20150299282A1 (en)
EP (2)	EP3679944B1 (en)
JP (4)	JP6363613B2 (en)
KR (1)	KR101993393B1 (en)
CN (1)	CN104918632B (en)
AR (2)	AR093386A1 (en)
AU (3)	AU2013342324B2 (en)
BR (3)	BR122021003984B1 (en)
CA (1)	CA2890329C (en)
CL (1)	CL2015001207A1 (en)
DK (1)	DK2916860T3 (en)
EA (2)	EA031928B1 (en)
ES (1)	ES2802099T3 (en)
HR (1)	HRP20200925T1 (en)
HU (1)	HUE049240T2 (en)
IL (2)	IL238631B (en)
LT (1)	LT2916860T (en)
MX (2)	MX360335B (en)
MY (1)	MY173828A (en)
NZ (2)	NZ708105A (en)
PE (1)	PE20151420A1 (en)
PH (2)	PH12015501009B1 (en)
PL (1)	PL2916860T3 (en)
PT (1)	PT2916860T (en)
SG (3)	SG10202110636WA (en)
TW (4)	TWI741218B (en)
UA (1)	UA117570C2 (en)
WO (1)	WO2014073845A1 (en)
ZA (1)	ZA201503999B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR086866A1 (en)	2011-06-10	2014-01-29	Hanmi Science Co Ltd	DERIVATIVES OF OXINTOMODULIN AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM FOR THE TREATMENT OF OBESITY
PT2721062T (en)	2011-06-17	2019-02-12	Hanmi Science Co Ltd	A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
KR20130049671A (en)	2011-11-04	2013-05-14	한미사이언스 주식회사	Method for preparation of biological active polypeptide conjugate
AR090281A1 (en)	2012-03-08	2014-10-29	Hanmi Science Co Ltd	IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
KR101968344B1 (en)	2012-07-25	2019-04-12	한미약품 주식회사	A composition for treating hyperlipidemia comprising oxyntomodulin analog
UA116217C2 (en)	2012-10-09	2018-02-26	Санофі	Exendin-4 derivatives as dual glp1/glucagon agonists
KR101993393B1 (en)	2012-11-06	2019-10-01	한미약품 주식회사	A composition for treating diabetes or diabesity comprising oxyntomodulin analog
KR102311517B1 (en)	2012-11-06	2021-10-14	한미약품 주식회사	Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
TW201609797A (en)	2013-12-13	2016-03-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists
TW201609796A (en)	2013-12-13	2016-03-16	賽諾菲公司	Non-acylated EXENDIN-4 peptide analogues
EP4464332A1 (en) *	2014-03-31	2024-11-20	Hanmi Pharm. Co., Ltd.	Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
TW201625670A (en)	2014-04-07	2016-07-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en)	2014-04-07	2016-07-16	賽諾菲公司	Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en)	2014-04-07	2016-07-16	賽諾菲公司	Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TWI684458B (en) *	2014-05-30	2020-02-11	南韓商韓美藥品股份有限公司	Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TWI772252B (en)	2014-09-16	2022-08-01	南韓商韓美藥品股份有限公司	Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
US11135271B2 (en) *	2014-12-30	2021-10-05	Hanmi Pharm. Co., Ltd.	Glucagon derivatives with improved stability
KR102418477B1 (en)	2014-12-30	2022-07-08	한미약품 주식회사	Gluagon Derivatives
AR105319A1 (en)	2015-06-05	2017-09-27	Sanofi Sa	PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
US10696725B2 (en)	2015-06-30	2020-06-30	Hanmi Pharm. Co., Ltd.	Glucagon derivative and a composition comprising a long acting conjugate of the same
AR105284A1 (en)	2015-07-10	2017-09-20	Sanofi Sa	DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
MA43348A (en)	2015-10-01	2018-08-08	Novo Nordisk As	PROTEIN CONJUGATES
EP3359191A4 (en)	2015-10-05	2019-05-29	Merck Sharp & Dohme Corp.	ANTIBODY-PEPTIDE CONJUGATES HAVING AGONIST ACTIVITY AT GLUCAGON AND PEPTIDE-1 RECEPTORS SIMILAR TO GLUCAGON
WO2017062271A2 (en)	2015-10-06	2017-04-13	Merck Sharp & Dohme Corp.	Antibody drug conjugate for anti-inflammatory applications
CN116063453A (en)	2015-12-31	2023-05-05	韩美药品株式会社	glucagon/GLP-1/GIP receptor triple agonists
WO2017132103A2 (en)	2016-01-29	2017-08-03	Merck Sharp & Dohme Corp.	Phosphonate linkers and their use to facilitate cellular retention of compounds
KR101887576B1 (en) *	2016-04-15	2018-08-13	(주)케어젠	Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
TN2018000452A1 (en) *	2016-06-29	2020-06-15	Hanmi Pharm Ind Co Ltd	Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
RU2764197C1 (en)	2016-09-23	2022-01-14	Ханми Фарм. Ко., Лтд.	Insulin analogues with reduced affinity to insulin receptor and their use
CN108299554B (en) *	2017-01-13	2021-05-25	博瑞生物医药（苏州）股份有限公司	Oxyntomodulin analogues
CN106986924A (en) *	2017-03-23	2017-07-28	中国药科大学	Oxyntomodulin（OXM）Analog and its application
WO2018174668A2 (en)	2017-03-23	2018-09-27	한미약품 주식회사	Insulin analog complex with reduced affinity for insulin receptor and use thereof
WO2019066603A1 (en) *	2017-09-29	2019-04-04	한미약품 주식회사	Persistent protein conjugate with improved efficiency
WO2019171352A2 (en) *	2018-03-08	2019-09-12	Janssen Pharmaceutica Nv	Methods of treating severe non-diabetic obesity
KR20200135618A (en) *	2019-05-23	2020-12-03	㈜ 디앤디파마텍	Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease comprising a polypeptide
EP3823659A4 (en)	2018-07-19	2022-06-22	D&D Pharmatech Inc.	Pharmaceutical composition comprising polypeptide
WO2020017919A1 (en) *	2018-07-19	2020-01-23	한미정밀화학주식회사	Novel intermediate used for physiologically active polypeptide and method for preparing same
US11929171B2 (en)	2018-10-18	2024-03-12	The Board Of Trustees Of The Leland Stanford Junior University	Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof
US12441776B2 (en)	2018-11-30	2025-10-14	Eirgen Pharma Ltd.	Oxyntomodulin peptide analog formulations
WO2020128967A2 (en) *	2018-12-19	2020-06-25	Janssen Pharmaceutica Nv	Methods of treating severe non-diabetic obesity
KR20210118857A (en) *	2019-02-15	2021-10-01	한미정밀화학주식회사	Novel intermediates used for bioactive polypeptides and methods for their preparation
KR102094103B1 (en) *	2019-05-08	2020-03-27	㈜ 디앤디파마텍	Pharmaceutical composition for preventing or treating diabetes comprising a polypeptide
US20240002474A1 (en) *	2020-11-16	2024-01-04	The Board Of Trustees Of The Leland Stanford Junior University	Systems and Methods for Diagnostic Assessment and Treatment of Insulin Resistance and Hyperglycemia
CN121064327A (en) *	2024-06-03	2025-12-05	信达生物制药(苏州)有限公司	Regulators of GIPR, GLP1R and/or GCGR and their uses

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (en)	1996-03-18	2008-02-13	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	Immunoglobulin-like domain with increased half-life
JP3895109B2 (en)	1998-03-06	2007-03-22	中外製薬株式会社	Protein-free formulation
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
US6677136B2 (en)	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
US7217845B2 (en)	2002-11-25	2007-05-15	Sun Bio, Inc.	Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
EP1594530A4 (en)	2003-01-22	2006-10-11	Human Genome Sciences Inc	Albumin fusion proteins
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en)	2003-10-16	2005-04-21	Compugen Ltd.	Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
JP4762904B2 (en) *	2003-11-13	2011-08-31	ハンミホールディングスカンパニーリミテッド	Mass production method of immunoglobulin constant region
US8263084B2 (en) *	2003-11-13	2012-09-11	Hanmi Science Co., Ltd	Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (en)	2007-11-29	2012-04-24	한미사이언스 주식회사	A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US20090238838A1 (en)	2003-11-13	2009-09-24	Hanmi Pharm. Ind. Co. Ltd.	Insulinotropic peptide conjugate using an immunoglobulin fc
EP1841796A2 (en)	2004-12-02	2007-10-10	Domantis Limited	Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
AU2006213607A1 (en)	2005-02-11	2006-08-17	Amylin Pharmaceuticals, Llc	GIP analog and hybrid polypeptides with selectable properties
KR100754667B1 (en)	2005-04-08	2007-09-03	한미약품 주식회사	Immunoglobulin Fc Fragments Modified with Non-Peptide Polymers and Pharmaceutical Compositions Comprising the Same
PL1891105T3 (en)	2005-06-13	2012-09-28	Imperial Innovations Ltd	Oxyntomodulin analogues and their effects on feeding behaviour
GB0511986D0 (en)	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
EP1922336B1 (en)	2005-08-11	2012-11-21	Amylin Pharmaceuticals, LLC	Hybrid polypeptides with selectable properties
WO2007100535A2 (en)	2006-02-22	2007-09-07	Merck & Co., Inc.	Oxyntomodulin derivatives
CA2654055A1 (en)	2006-06-07	2007-12-21	Human Genome Sciences, Inc.	Albumin fusion proteins
GB0624868D0 (en)	2006-12-13	2007-01-24	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
TWI428346B (en)	2006-12-13	2014-03-01	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
US20090098130A1 (en)	2007-01-05	2009-04-16	Bradshaw Curt W	Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (en)	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	Insulin secretory peptide drug conjugates using carrier substances
JP6017754B2 (en)	2007-02-15	2016-11-02	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	Glucagon / GLP-1 receptor co-agonist
BRPI0813699B1 (en)	2007-07-10	2021-06-22	Eli Lilly And Company	GLP-1-FC FUSION PROTEIN FORMULATION
WO2009040068A2 (en)	2007-09-11	2009-04-02	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
CA2702289A1 (en)	2007-10-30	2009-05-07	Indiana University Research And Technology Corporation	Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP2011511778A (en)	2008-01-30	2011-04-14	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーション	Ester-based peptide prodrugs
CA2728284C (en)	2008-06-17	2019-09-10	Richard D. Dimarchi	Glucagon/glp-1 receptor co-agonists
EP2307037A4 (en)	2008-06-17	2011-08-03	Univ Indiana Res & Tech Corp	GLUCAGON ANALOGUES HAVING PHYSIOLOGICAL PH BUFFERS HAVING ENHANCED SOLUBILITY AND STABILITY
WO2010013012A2 (en)	2008-08-01	2010-02-04	Lund University Bioscience Ab	Novel polypeptides and uses thereof
US20110171312A1 (en)	2008-09-19	2011-07-14	Nektar Therapeutics	Modified therapeutic peptides, methods of their preparation and use
EP2898900B1 (en)	2008-09-19	2017-11-15	Nektar Therapeutics	Polymer conjugates of ziconotide
PL2370461T3 (en)	2008-12-15	2014-03-31	Zealand Pharma As	Glucagon analogues
AR074811A1 (en)	2008-12-19	2011-02-16	Univ Indiana Res & Tech Corp	PEPTIDE PROFARMACY OF THE GLUCAGON SUPERFAMILY BASED IN AMIDA
WO2010096052A1 (en) *	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
DK2408800T3 (en)	2009-03-20	2016-08-29	Hanmi Science Co Ltd	A process for the preparation of a site-specific conjugate of a physiologically active polypeptide
CA2755133A1 (en)	2009-03-20	2010-09-23	Amgen Inc.	Selective and potent peptide inhibitors of kv1.3
US9150632B2 (en)	2009-06-16	2015-10-06	Indiana University Research And Technology Corporation	GIP receptor-active glucagon compounds
US9156901B2 (en)	2009-07-13	2015-10-13	Ditte Riber	Acylated glucagon analogues
US20120294855A1 (en)	2009-11-03	2012-11-22	Eli Lilly & Company	Glp-1 receptor agonist compounds for obstructive sleep apnea
US20120269830A1 (en)	2009-12-07	2012-10-25	Lawrence Horowitz	Conjugates with improved pharmacokinetic properties
US8703701B2 (en) *	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
AR079344A1 (en)	2009-12-22	2012-01-18	Lilly Co Eli	PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
AR079345A1 (en) *	2009-12-22	2012-01-18	Lilly Co Eli	OXINTOMODULINE PEPTIDAL ANALOG
WO2011117415A1 (en)	2010-03-26	2011-09-29	Novo Nordisk A/S	Novel glucagon analogues
KR20130111923A (en)	2010-05-13	2013-10-11	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
CA2796894A1 (en)	2010-06-24	2011-12-29	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
KR101382593B1 (en)	2010-07-21	2014-04-10	한미사이언스 주식회사	Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
CN101974077A (en)	2010-09-15	2011-02-16	南京瑞年天平医药科技有限公司	Novel polypeptide compound
KR101767570B1 (en) *	2010-10-26	2017-08-14	한미사이언스 주식회사	A long-lasting conjugate of An anti-obesity peptide derivative complex
KR101303388B1 (en)	2010-10-26	2013-09-03	한미사이언스 주식회사	Liquid formulations of long acting interferon alpha conjugate
CN102010473A (en) *	2010-11-10	2011-04-13	曹鹏	Recombinant oxyntomodulin (OXM) fusion protein, and preparation and application thereof
US8975223B2 (en)	2010-12-22	2015-03-10	Marcadia Biotech, Inc.	Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146
JP6118500B2 (en)	2011-02-28	2017-04-19	ロームアンドハースエレクトロニックマテリアルズエルエルシーＲｏｈｍａｎｄＨａａｓＥｌｅｃｔｒｏｎｉｃＭａｔｅｒｉａｌｓＬＬＣ	Photoresist composition and method for forming photolithography pattern
KR101161526B1 (en)	2011-05-16	2012-07-02	숭실대학교산학협력단	Catalyst electrode of core/shell nanostructure supports and method of it for fuel cell
AR086866A1 (en)	2011-06-10	2014-01-29	Hanmi Science Co Ltd	DERIVATIVES OF OXINTOMODULIN AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM FOR THE TREATMENT OF OBESITY
PT2721062T (en) *	2011-06-17	2019-02-12	Hanmi Science Co Ltd	A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
EP2723766A4 (en)	2011-06-22	2015-05-20	Univ Indiana Res & Tech Corp	CO-AGONISTS OF THE GLUCAGON RECEPTOR AND THE LPG-1 RECEPTOR
SG11201406671RA (en)	2012-04-19	2014-11-27	Opko Biolog Ltd	Long-acting oxyntomodulin variants and methods of producing same
US9340600B2 (en)	2012-06-21	2016-05-17	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
KR101968344B1 (en) *	2012-07-25	2019-04-12	한미약품 주식회사	A composition for treating hyperlipidemia comprising oxyntomodulin analog
AR092873A1 (en)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS
KR102311517B1 (en)	2012-11-06	2021-10-14	한미약품 주식회사	Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (en) *	2012-11-06	2019-10-01	한미약품 주식회사	A composition for treating diabetes or diabesity comprising oxyntomodulin analog
JP6137046B2 (en)	2014-05-09	2017-05-31	信越化学工業株式会社	Monomer, polymer compound, resist material and pattern forming method

2012
- 2012-11-06 KR KR1020120124724A patent/KR101993393B1/en active Active
2013
- 2013-06-11 UA UAA201504676A patent/UA117570C2/en unknown
- 2013-11-06 EA EA201590759A patent/EA031928B1/en not_active IP Right Cessation
- 2013-11-06 LT LTEP13853226.2T patent/LT2916860T/en unknown
- 2013-11-06 AU AU2013342324A patent/AU2013342324B2/en active Active
- 2013-11-06 ES ES13853226T patent/ES2802099T3/en active Active
- 2013-11-06 MX MX2015005699A patent/MX360335B/en active IP Right Grant
- 2013-11-06 SG SG10202110636WA patent/SG10202110636WA/en unknown
- 2013-11-06 TW TW107133431A patent/TWI741218B/en active
- 2013-11-06 AR ARP130104070A patent/AR093386A1/en not_active Application Discontinuation
- 2013-11-06 TW TW110124452A patent/TWI755341B/en active
- 2013-11-06 TW TW102140248A patent/TWI645856B/en active
- 2013-11-06 PT PT138532262T patent/PT2916860T/en unknown
- 2013-11-06 US US14/440,653 patent/US20150299282A1/en not_active Abandoned
- 2013-11-06 HU HUE13853226A patent/HUE049240T2/en unknown
- 2013-11-06 BR BR122021003984-4A patent/BR122021003984B1/en active IP Right Grant
- 2013-11-06 BR BR122019024272-0A patent/BR122019024272B1/en active IP Right Grant
- 2013-11-06 SG SG10201703732VA patent/SG10201703732VA/en unknown
- 2013-11-06 WO PCT/KR2013/009990 patent/WO2014073845A1/en not_active Ceased
- 2013-11-06 CN CN201380069535.8A patent/CN104918632B/en active Active
- 2013-11-06 PE PE2015000594A patent/PE20151420A1/en not_active Application Discontinuation
- 2013-11-06 DK DK13853226.2T patent/DK2916860T3/en active
- 2013-11-06 MX MX2018012968A patent/MX378848B/en unknown
- 2013-11-06 SG SG11201503420QA patent/SG11201503420QA/en unknown
- 2013-11-06 TW TW109122403A patent/TWI754980B/en active
- 2013-11-06 EP EP20151111.0A patent/EP3679944B1/en active Active
- 2013-11-06 PL PL13853226T patent/PL2916860T3/en unknown
- 2013-11-06 EA EA201892383A patent/EA037956B1/en unknown
- 2013-11-06 NZ NZ708105A patent/NZ708105A/en unknown
- 2013-11-06 MY MYPI2015001149A patent/MY173828A/en unknown
- 2013-11-06 NZ NZ738835A patent/NZ738835A/en unknown
- 2013-11-06 EP EP13853226.2A patent/EP2916860B1/en active Active
- 2013-11-06 CA CA2890329A patent/CA2890329C/en active Active
- 2013-11-06 JP JP2015540614A patent/JP6363613B2/en active Active
- 2013-11-06 BR BR112015010203-4A patent/BR112015010203B1/en active IP Right Grant
- 2013-11-06 HR HRP20200925TT patent/HRP20200925T1/en unknown
2015
- 2015-05-04 IL IL238631A patent/IL238631B/en active IP Right Grant
- 2015-05-06 PH PH12015501009A patent/PH12015501009B1/en unknown
- 2015-05-06 CL CL2015001207A patent/CL2015001207A1/en unknown
- 2015-06-04 ZA ZA2015/03999A patent/ZA201503999B/en unknown
2018
- 2018-01-08 AU AU2018200138A patent/AU2018200138B2/en active Active
- 2018-04-23 US US15/960,205 patent/US10550168B2/en active Active
- 2018-06-28 JP JP2018123263A patent/JP6666959B2/en active Active
- 2018-07-03 PH PH12018501424A patent/PH12018501424B1/en unknown
2019
- 2019-12-04 AU AU2019275590A patent/AU2019275590B2/en active Active
2020
- 2020-02-21 JP JP2020028080A patent/JP7050834B2/en active Active
- 2020-03-15 IL IL273305A patent/IL273305B/en unknown
2022
- 2022-02-04 JP JP2022016603A patent/JP7341263B2/en active Active
- 2022-08-23 AR ARP220102265A patent/AR126851A2/en unknown

Also Published As

Publication number	Publication date
JP2022048398A (en)	2022-03-25
AU2018200138B2 (en)	2019-09-12
IL238631B (en)	2020-04-30
BR112015010203A8 (en)	2019-11-26
MX2015005699A (en)	2016-02-05
EP2916860B1 (en)	2020-03-11
PH12015501009A1 (en)	2015-07-27
PE20151420A1 (en)	2015-09-24
BR122021003984B1 (en)	2022-07-12
MX360335B (en)	2018-10-29
NZ708105A (en)	2018-06-29
CL2015001207A1 (en)	2015-07-03
EP2916860A1 (en)	2015-09-16
NZ748034A (en)	2020-10-30
SG11201503420QA (en)	2015-05-28
UA117570C2 (en)	2018-08-27
IL273305A (en)	2020-04-30
NZ738835A (en)	2020-03-27
BR112015010203B1 (en)	2021-05-18
TWI755341B (en)	2022-02-11
EP3679944A1 (en)	2020-07-15
IL273305B (en)	2021-10-31
JP2015536943A (en)	2015-12-24
JP6666959B2 (en)	2020-03-18
CA2890329A1 (en)	2014-05-15
US20150299282A1 (en)	2015-10-22
ES2802099T3 (en)	2021-01-15
AR126851A2 (en)	2023-11-22
CA2890329C (en)	2024-01-23
TW202041528A (en)	2020-11-16
EP2916860A4 (en)	2016-06-22
EA037956B1 (en)	2021-06-15
TW201900206A (en)	2019-01-01
JP7050834B2 (en)	2022-04-08
BR112015010203A2 (en)	2017-08-22
AR093386A1 (en)	2015-06-03
EP3679944B1 (en)	2022-03-30
TW201422232A (en)	2014-06-16
US20180237490A1 (en)	2018-08-23
TWI754980B (en)	2022-02-11
EA201590759A1 (en)	2015-12-30
SG10202110636WA (en)	2021-11-29
AU2013342324A1 (en)	2015-05-28
TWI741218B (en)	2021-10-01
TW202144394A (en)	2021-12-01
ZA201503999B (en)	2016-07-27
DK2916860T3 (en)	2020-06-15
US10550168B2 (en)	2020-02-04
IL238631A0 (en)	2015-06-30
MY173828A (en)	2020-02-24
AU2019275590A1 (en)	2020-01-02
AU2018200138A1 (en)	2018-02-01
AU2013342324B2 (en)	2018-02-22
BR122019024272B1 (en)	2021-05-18
PH12018501424A1 (en)	2019-04-01
PH12015501009B1 (en)	2019-03-06
HUE049240T2 (en)	2020-09-28
CN104918632A (en)	2015-09-16
TWI645856B (en)	2019-01-01
CN104918632B (en)	2017-10-31
JP6363613B2 (en)	2018-07-25
KR101993393B1 (en)	2019-10-01
PL2916860T3 (en)	2020-11-02
PH12018501424B1 (en)	2022-04-06
JP2018162298A (en)	2018-10-18
JP2020079301A (en)	2020-05-28
AU2019275590B2 (en)	2022-01-20
WO2014073845A1 (en)	2014-05-15
LT2916860T (en)	2020-07-10
HK1211856A1 (en)	2016-06-03
JP7341263B2 (en)	2023-09-08
EA031928B1 (en)	2019-03-29
KR20140058104A (en)	2014-05-14
HRP20200925T1 (en)	2020-09-18
MX378848B (en)	2025-03-11
EA201892383A1 (en)	2019-03-29
PT2916860T (en)	2020-07-02

Publication	Publication Date	Title
IL273305B (en)	2021-10-31	A composition for treating diabetes or diabesity comprising oxyntomodulin analog
IL274106B1 (en)	2023-04-01	Composition for treating hyperlipidemia comprising oxyntomodulin derivative
IL268984B (en)	2021-04-29	Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
EP2902020A4 (en)	2016-03-23	Composition for reducing new-onset diabetes
ZA201500808B (en)	2016-10-26	Composition for controlling plant disease and application therefor
IL220889A (en)	2017-07-31	Anti-dll4 antibody for treating diabetes
EP2867239A4 (en)	2015-12-23	Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
EP2774917A4 (en)	2015-05-06	Pharmaceutical composition for treating diabetes
SG10201700525PA (en)	2017-02-27	Composition for preventing or treating osteoarthritis
PL2534302T3 (en)	2020-10-19	Surface treatment composition
EP2875731A4 (en)	2015-12-30	Composition for controlling plant disease and application therefor
EP2812190A4 (en)	2014-12-17	Surface treatment composition
SG11201501289TA (en)	2015-04-29	Preparation for preventing or treating type i diabetes
ZA201408065B (en)	2016-04-28	Compositions and methods for the treatment of diabetes
ZA201204341B (en)	2013-08-28	Pharmaceutical composition for treating gutaneous burns
SI2617412T1 (en)	2016-04-29	Composition for topical treatment
IL238331A0 (en)	2015-06-30	Method for treating type 1 and type ii diabetes
PL2768527T3 (en)	2017-12-29	Multi-cbv vaccine for preventing or treating type 1 diabetes
EP2785343A4 (en)	2015-04-15	Pharmaceutical composition for preventing or treating hyperlipidemia
GB201016834D0 (en)	2010-11-17	Composition for skin treatment
GB201016836D0 (en)	2010-11-17	Composition for skin treatment
GB201001900D0 (en)	2010-03-24	Transdermal delivery composition
IL213610A0 (en)	2011-07-31	Composition for treating dermatological conditions
GB201110659D0 (en)	2011-08-10	composition for skin treatment
GB201110653D0 (en)	2011-08-10	Composition for skin treatment